The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Regorafenib and nivolumab combination therapy for advanced and metastatic solid tumors: Phase I clinical trial (EPOC1603).
 
Shota Fukuoka
No Relationships to Disclose
 
Hiroki Hara
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Merck Serono; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); LSK BioPharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Satoshi Shimizu
Honoraria - Novartis; Taiho Pharmaceutical
 
Hideaki Takahashi
Honoraria - Bayer; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly Japan; Nobelpharma; Novartis; Otsuka; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Bristol-Myers Squibb Japan; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; MSD; NanoCarrier; Novartis; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Baxalta/Shire; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takara Bio; Yakult Pharmaceutical; Zeria Pharmaceutical
 
Hitomi Tamura
No Relationships to Disclose
 
Yuichi Mikamoto
No Relationships to Disclose
 
Miki Fukutani
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Chugai Pharma
 
Shogo Nomura
Employment - Asahi Kasei (I)
 
Akihiro Sato
Honoraria - AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)